Making the discoveries that defeat cancer

  • Home |
  • About Us  |
  • Research  |
  • Enterprise  |
  • Education  |
  • Jobs  |
  • Support Us  |
  • News  |
  • Contact Us
  • Home »
  • Research »
  • Research Divisions »
  • Division of Clinical Studies »
  • Clinical Trials and Statistics Unit »
  • Trials by Disease »
  • Clinical Trials of Other Cancers

Research

  • ICR Ranking on RAE
  • Research Highlights
  • Publications Repository
  • Research Divisions
  • Team Leaders
  • Biomedical Research Centre
  • REF 2014

Other Cancer Clinical Trials

Open to recruitment

CASPS: A Phase II trial of Cediranib in the treatment of patients with Alveolar Soft Part Sarcoma

In active follow-up

ICCG FEMTX Trial: Adjuvant phase III randomised study of high dose methotrexate and 5-Fluorouracil combined with epirubicin (FEMTX) versus control in patients with resected gastric cancer.

Closed to recruitment

MARS: Mesothelioma and radical surgery trial.

Show/ hide: In the Clinical Trials SectionIn the Clinical Trials Section

  • Breast Cancer Clinical Trials
  • Head & Neck Clinical Trials
  • Melanoma Clinical Trials
  • Urological Cancers Clinical Trials
  • Clinical Trials of Other Cancers

Trials by disease site:

  • Breast Cancer Clinical Trials
  • Other Cancer Clinical Trials
  • Urological Cancer Clinical Trials
  • Head & Neck Cancer Clinical Trials
  • Melanoma Clinical Trials

Trials by treatment modality:

  • Combination Therapy Clinical Trials
  • Hormone Therapy Clinical Trials
  • Surgical Treatment Clinical Trials
  • Radiotherapy Clinical Trials
  • Clinical Trials of Other Treatments
  • Chemotherapy Clinical Trials

Other Cancers Clinical Trials

Open to recruitment

  • CASPS

In active follow-up

  • ICCG FEMTX Trial

Closed to recruitment

  • MARS


Last updated: 24 June 2011

The Royal Marsden - NHS foundation trust
  • Contacts  | 
  • Privacy  | 
  • Terms and Conditions  | 
  • Accessibility  | 
  • Feedback  | 
  • Cookies  | 
  • Status
  • ICR News RSS Feed
  • Find us on Facebook
  • Follow us on Twitter